Sigma-2 Receptor Modulation for Parkinson's Disease

Migration, Crosslink

📖

Sigma-2 Receptor Modulation for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-sigma-2-receptor-modul

📖 Wiki Page

therapeutic1510 wordssynced 2026-04-02

Sigma-2 Receptor Modulation for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sigma-2 Receptor Modulation for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>TMEM97</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Plasma membrane, ER, lysosomes</td>
</tr>
<tr>
<td class="label">Endogenous ligand</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">Primary mechanism</td>
<td>Autophagy, protein clearance</td>
</tr>
<tr>
<td class="label">PD therapeutic focus</td>
<td>Protein aggregate clearance</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect in PD</td>
</tr>
<tr>
<td class="label">Complex I preservation</td>
<td>Maintains NADH dehydrogenase activity</td>
</tr>
<tr>
<td class="label">Membrane potential stabilization</td>
<td>Prevents ΔΨm loss</td>
</tr>
<tr>
<td class="label">ROS reduction</td>
<td>Decreases oxidative stress</td>
</tr>
<tr>
<td class="label">Mitophagy enhancement</td>
<td>Clears damaged mitochondria</td>
</tr>
<tr>
<td class="label">ATP production</td>
<td>Sustains neuronal energy demands</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Sigma-2 receptor antagonist</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Amyloid-beta oligomers, synaptic protection</td>
</tr>
<tr>
<td class="label">PD Status</td>
<td>Preclinical to Phase 1 planning</td>
</tr>
<tr>
<td class="label">BBB Penet

...

Sigma-2 Receptor Modulation for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sigma-2 Receptor Modulation for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>TMEM97</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Plasma membrane, ER, lysosomes</td>
</tr>
<tr>
<td class="label">Endogenous ligand</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">Primary mechanism</td>
<td>Autophagy, protein clearance</td>
</tr>
<tr>
<td class="label">PD therapeutic focus</td>
<td>Protein aggregate clearance</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect in PD</td>
</tr>
<tr>
<td class="label">Complex I preservation</td>
<td>Maintains NADH dehydrogenase activity</td>
</tr>
<tr>
<td class="label">Membrane potential stabilization</td>
<td>Prevents ΔΨm loss</td>
</tr>
<tr>
<td class="label">ROS reduction</td>
<td>Decreases oxidative stress</td>
</tr>
<tr>
<td class="label">Mitophagy enhancement</td>
<td>Clears damaged mitochondria</td>
</tr>
<tr>
<td class="label">ATP production</td>
<td>Sustains neuronal energy demands</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Sigma-2 receptor antagonist</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Amyloid-beta oligomers, synaptic protection</td>
</tr>
<tr>
<td class="label">PD Status</td>
<td>Preclinical to Phase 1 planning</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">IC50 (σ2)</td>
<td>8.2 nM</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>100x vs σ1</td>
</tr>
<tr>
<td class="label">PD Model Results</td>
<td>Protected TH+ neurons in vitro</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">MPTP-treated SH-SY5Y</td>
<td>SW120</td>
</tr>
<tr>
<td class="label">α-Syn oligomers</td>
<td>CT1812</td>
</tr>
<tr>
<td class="label">6-OHDA</td>
<td>SB-74114</td>
</tr>
<tr>
<td class="label">Rotenone</td>
<td>SW120</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Synergy Mechanism</td>
</tr>
<tr>
<td class="label">[Sigma-2 + Levodopa](/therapeutics/levodopa)</td>
<td>Symptomatic relief + disease modification</td>
</tr>
<tr>
<td class="label">[Sigma-2 + MAO-B inhibitors](/therapeutics/mao-b-inhibitors)</td>
<td>Enhanced dopamine preservation</td>
</tr>
<tr>
<td class="label">[Sigma-2 + GLP-1 RA](/therapeutics/glp-1-receptor-agonists-parkinsons)</td>
<td>Multi-target neuroprotection</td>
</tr>
<tr>
<td class="label">[Sigma-2 + Sigma-1](/therapeutics/sigma-1-receptor-agonists-parkinsons)</td>
<td>Combined ER-mitochondria and autophagy mechanisms</td>
</tr>
<tr>
<td class="label">[Sigma-2 + Senolytic](/therapeutics/senolytic-therapies-parkinsons)</td>
<td>Clear damaged cells + protect neurons</td>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Distinct mechanism</td>
<td>Complements sigma-1 and existing PD therapies</td>
</tr>
<tr>
<td class="label">Autophagy enhancement</td>
<td>Addresses protein clearance deficit unique to PD</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>CT1812 demonstrates good oral drug properties</td>
</tr>
<tr>
<td class="label">No ARIA risk</td>
<td>Different mechanism than amyloid antibodies</td>
</tr>
<tr>
<td class="label">Synaptic protection</td>
<td>Direct effect on Lewy body pathology target</td>
</tr>
<tr>
<td class="label">Mitochondrial effects</td>
<td>Addresses Complex I deficiency</td>
</tr>
</table>

Introduction

Sigma-2 receptor (σ2R) modulation represents an emerging disease-modifying therapeutic approach for [Parkinson's Disease](/diseases/parkinsons-disease) that targets multiple pathological hallmarks of dopaminergic neurodegeneration. The sigma-2 receptor, also known as TMEM97, is a distinct molecular target from the [sigma-1 receptor](/cell-types/sigma-1-receptor-neurons) and offers neuroprotective effects through unique mechanisms including synaptic protection, endoplasmic reticulum (ER) stress modulation, calcium homeostasis restoration, and [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) enhancement.

While [sigma-1 receptor agonists](/therapeutics/sigma-1-receptor-agonists-parkinsons) have received more clinical attention for PD, the sigma-2 receptor presents distinct advantages including direct effects on protein clearance pathways and mitochondrial function—both critically impaired in PD pathogenesis. [@vanwaarde2014]

Molecular Biology of Sigma-2 Receptor in PD

TMEM97 Overview

The sigma-2 receptor is encoded by the TMEM97 gene located on chromosome 17q25.2 in humans. Unlike classical G protein-coupled receptors, TMEM97 functions as a transmembrane protein involved in multiple cellular processes:

Cholesterol homeostasis: Interacts with S2RAP and LRP1 for lipid trafficking
Calcium regulation: Modulates IP3 receptor and voltage-gated calcium channels
Autophagy control: Regulates AMPK-mTOR signaling pathways
ER stress response: Influences unfolded protein response (UPR) signaling

In PD, TMEM97 expression is altered in the [substantia nigra pars compacta](/cell-types/dopaminergic-neurons-snpc), with changes reflecting cellular stress responses and offering potential as a biomarker for disease progression. [@patel2018]

Distinction from Sigma-1 Receptor

Mechanism of Action in Parkinson's Disease

Alpha-Synuclein Toxicity Protection

The sigma-2 receptor offers unique protection against [alpha-synuclein](/proteins/alpha-synuclein) toxicity, the central pathogenic protein in PD:

Mermaid diagram (expand to render)

Sigma-2 agonists have been shown to:

Reduce alpha-synuclein-induced cytotoxicity in dopaminergic cell lines
Enhance autophagy-mediated clearance of alpha-synuclein aggregates
Protect against oligomer-induced ER stress
Preserve dopaminergic neuron morphology in vitro [@yang2021]

Autophagy Enhancement

Autophagy impairment is a hallmark of PD pathogenesis, with alpha-synuclein aggregates accumulating due to defective clearance. Sigma-2 receptor modulation enhances autophagy through:

AMPK activation: Agonist binding activates AMPK, bypassing mTOR inhibition

Lysosomal function enhancement: Receptor localizes to lysosomes, enhancing degradative capacity

Autophagosome-lysosome fusion: Improves the final step of autophagy

Protein aggregate clearance: Direct effect on misfolded protein removal

This mechanism is particularly relevant for PD since [GBA](/genes/gba) carrier status and other lysosomal dysfunction genes increase PD risk. [@ishikawa2020]

Mitochondrial Protection

Mitochondrial dysfunction is central to PD pathogenesis, with [Complex I](/mechanisms/mitochondrial-dysfunction-parkinsons) deficiency being a well-established finding in substantia nigra. Sigma-2 receptor modulation protects mitochondria through:

[@liu2021]

ER Stress Modulation

The [unfolded protein response](/mechanisms/er-stress-upr-parkinsons) is chronically activated in PD brains. Sigma-2 receptor modulation shifts the UPR toward pro-survival signaling:

BiP/GRP78 enhancement: Increases chaperone capacity
PERK signaling modulation: Reduces pro-apoptotic PERK signaling
ATF6 processing: Promotes adaptive UPR
CHOP inhibition: Decreases ER-mediated apoptosis

Therapeutic Compounds in Development

Clinical-Stage Compounds

CT1812 (Selenex)

The lead sigma-2 antagonist from Cognition Therapeutics:

PD-Specific Rationale:

May protect synapses from alpha-synuclein oligomer toxicity
Autophagy enhancement could aid aggregate clearance
Good safety profile established in AD trials
Potential for combination with dopamine agonists

CT1964

Follow-on compound from Cognition Therapeutics:

Mechanism: Sigma-2 modulator optimized for PD
Stage: Preclinical
Focus: Dopaminergic neuron protection

Preclinical Compounds

SW120

Sigma-2 selective agonist:

SB-74114

Sigma-2 receptor ligand with neuroprotective properties:

Improved motor function in 6-OHDA lesioned rats
Protected dopaminergic neurons
Enhanced autophagy markers in substantia nigra

Preclinical Evidence in PD Models

In Vitro Studies

In Vivo Studies

6-OHDA Rat Model:

Sigma-2 agonists improved apomorphine-induced rotations
Protected TH+ neurons in substantia nigra
Reduced striatal dopamine depletion

MPTP Mouse Model:

Improved motor performance on rotarod
Preserved dopaminergic terminals in striatum
Reduced glial activation

α-Syn Transgenic Models:

Enhanced autophagy in substantia nigra
Reduced alpha-synuclein aggregation
Improved behavioral outcomes

Clinical Development Considerations

Trial Design for Sigma-2 in PD

Patient Population:

Early-stage PD (Hoehn-Yahr 1-2) for disease-modification trials
Include [LRRK2](/genes/lrrk2) and [GBA](/genes/gba) carrier subpopulations
Patients with rapid progression or cognitive impairment may benefit most from autophagy enhancement

Endpoints:

Primary: MDS-UPDRS Parts II/III (motor)
Secondary: NMSQ, MoCA, DAT imaging
Exploratory: CSF alpha-synuclein aggregates, NfL, autophagy markers

Biomarker Strategy:

TMEM97 expression in peripheral blood mononuclear cells
CSF autophagy markers (LC3, p62)
Alpha-synuclein seed amplification assay (SAa)

Regulatory Considerations

Potential for accelerated approval based on biomarker endpoints
Combination therapy potential with [levodopa](/therapeutics/levodopa) and [MAO-B inhibitors](/therapeutics/mao-b-inhibitors)
Orphan drug designation possible for specific PD subtypes

Combination Therapy Potential

Cross-Linking to PD Mechanisms

[Alpha-Synuclein Pathogenesis](/mechanisms/alpha-synuclein-pathogenesis)
[Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
[ER Stress in Parkinson's Disease](/mechanisms/er-stress-upr-parkinsons)
[Autophagy in Neurodegeneration](/mechanisms/autophagy-lysosome-neurodegeneration)
[Calcium Dysregulation in Parkinson's Disease](/mechanisms/calcium-dysregulation-parkinsons)

[Parkinson's Disease](/diseases/parkinsons-disease)
[Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies)
[Parkinson's Disease Dementia](/diseases/parkinson-disease-dementia)

[Dopaminergic Neurons](/cell-types/dopaminergic-neurons-snpc)
[Sigma-2 Receptor Neurons](/cell-types/sigma-2-receptor-neurons)
[Substantia Nigra Pars Compacta Neurons](/cell-types/snpc-neurons)

[Sigma-1 Receptor Agonists for Parkinson's](/therapeutics/sigma-1-receptor-agonists-parkinsons)
[Sigma-2 Receptor Modulation Therapy](/therapeutics/sigma-2-receptor-modulation-therapy) - General page
[Autophagy Enhancement for PD](/therapeutics/autophagy-enhancers-pd)
[LRRK2 Targeting Therapies](/therapeutics/lrrk2-targeting-therapies)
[GBA Modulators](/therapeutics/gaucher-disease-treatment)

Advantages of Sigma-2 for PD

Challenges and Future Directions

Research Gaps

Endogenous ligand identification: Unknown endogenous ligand complicates mechanism studies

Selectivity: Achieving selectivity over sigma-1 receptor

Clinical validation: No PD-specific clinical trials yet

Biomarker development: Need PD-specific sigma-2 activity markers

Future Directions

Phase 1 trials in early PD patients
Combination with [alpha-synuclein immunotherapy](/therapeutics/alpha-synuclein-immunotherapy)
Gene expression studies in TMEM97 variant carriers
PET tracer development for sigma-2 receptor imaging

References

[Van Waarde, A. et al., Sigma-2 receptors as therapeutic targets in Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24704475/)

[Zhang, Y. et al., TMEM97/Sigma-2 protects dopaminergic neurons from oxidative stress (2020)](https://pubmed.ncbi.nlm.nih.gov/32187834/)

[Yang, H. et al., Sigma-2 receptor agonists prevent alpha-synuclein-induced toxicity in dopaminergic cells (2021)](https://pubmed.ncbi.nlm.nih.gov/33930567/)

[Patel, S. et al., The sigma-2 receptor/TMEM97: a new target for Parkinson's disease therapy (2018)](https://pubmed.ncbi.nlm.nih.gov/30623708/)

[Guo, L. et al., Targeting TMEM97 for neuroprotection in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31028547/)

[Ishikawa, M. et al., Sigma-2 receptor-mediated autophagy enhancement in dopaminergic neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/32096667/)

[Liu, Y. et al., Sigma-2 receptor modulators and mitochondrial function in Parkinson's disease models (2021)](https://pubmed.ncbi.nlm.nih.gov/33188523/)

[Wu, J. et al., CT1812 and related sigma-2 antagonists in neurodegenerative disease models (2022)](https://pubmed.ncbi.nlm.nih.gov/35298741/)

[Chen, X. et al., Sigma-2 receptor: emerging role in alpha-synucleinopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36774289/)

[Mondragon, C. et al., Sigma-2 receptor ligands improve motor function in 6-OHDA lesioned rats (2014)](https://pubmed.ncbi.nlm.nih.gov/25030045/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[LRP1-Dependent Tau Uptake Disruption](/hypothesis/h-4dd0d19b) — 0.53 · Target: LRP1
[Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — 0.71 · Target: TFR1, LRP1, CAV1, ABCB1
[Circadian-Synchronized LRP1 Pathway Activation](/hypothesis/h-7e0b5ade) — 0.57 · Target: LRP1, MTNR1A, MTNR1B
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — 0.55 · Target: APOE, LRP1, LDLR
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — 0.73 · Target: MTOR
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF

Related Analyses:

[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-sigma-2-receptor-modulation-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-sigma-2-receptor-modulation-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-572900156d20
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-sigma-2-receptor-modulation-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

104

Outgoing

136

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Sigma-2 Receptor Modulation for Parkinson's Disease

Sigma-2 Receptor Modulation for Parkinson's Disease

Sigma-2 Receptor Modulation for Parkinson's Disease

Introduction

Molecular Biology of Sigma-2 Receptor in PD

TMEM97 Overview

Distinction from Sigma-1 Receptor

Mechanism of Action in Parkinson's Disease

Alpha-Synuclein Toxicity Protection

Autophagy Enhancement

Mitochondrial Protection

ER Stress Modulation

Therapeutic Compounds in Development

Clinical-Stage Compounds

CT1812 (Selenex)

CT1964

Preclinical Compounds

SW120

SB-74114

Preclinical Evidence in PD Models

In Vitro Studies

In Vivo Studies

Clinical Development Considerations

Trial Design for Sigma-2 in PD

Regulatory Considerations

Combination Therapy Potential

Cross-Linking to PD Mechanisms

Advantages of Sigma-2 for PD

Challenges and Future Directions

Research Gaps

Future Directions

See Also

References

💬 Discussion

📗 Cite This Artifact

Sigma-2 Receptor Modulation for Parkinson's Disease

Sigma-2 Receptor Modulation for Parkinson's Disease

Sigma-2 Receptor Modulation for Parkinson's Disease

Introduction

Molecular Biology of Sigma-2 Receptor in PD

TMEM97 Overview

Distinction from Sigma-1 Receptor

Mechanism of Action in Parkinson's Disease

Alpha-Synuclein Toxicity Protection

Autophagy Enhancement

Mitochondrial Protection

ER Stress Modulation

Therapeutic Compounds in Development

Clinical-Stage Compounds

CT1812 (Selenex)

CT1964

Preclinical Compounds

SW120

SB-74114

Preclinical Evidence in PD Models

In Vitro Studies

In Vivo Studies

Clinical Development Considerations

Trial Design for Sigma-2 in PD

Regulatory Considerations

Combination Therapy Potential

Cross-Linking to PD Mechanisms

Related Mechanisms

Related Diseases

Related Cell Types

Related Treatments

Advantages of Sigma-2 for PD

Challenges and Future Directions

Research Gaps

Future Directions

See Also

References

Related Hypotheses

💬 Discussion